Vir Biotechnology, Inc. Form 8-K (April 13, 2021)
Summary
Form 8-K current report of Vir Biotechnology, Inc. dated April 13, 2021, filed under Item 8.01 (Other Events). It reports that on April 13, 2021 the company presented at the Needham & Company 20th Annual Healthcare Conference. A copy of the presentation is attached as Exhibit 99.1. The report is signed by Howard Horn.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Vir Biotechnology, Inc. Form 8-K (April 13, 2021).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-vir-8-k-filed2021-04-13-0001193125-21-114677-67dd598a87/
, SHA-256 a7eebb7c46ab75e21fb4dc0877472aa87866957b9d460bd1cc6ca3f7e3e85a81.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware | 001-39083 | 81-2730369 (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) 499 Illinois Street, Suite 500 San Francisco, California 94158 (Address of principal executive offices, including zip code) (415) 906-4324 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class | Trading Symbol(s) | Name of each exchange on which registered Common Stock, $0.0001 par value | VIR | Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01 Other Events. On April 13, 2021, Vir Biotechnology, Inc. presented at the Needham & Company 20 th Annual Healthcare Conference. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number | Description 99.1 | Presentation, dated April 13, 2021. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vir Biotechnology, Inc. By: | /s/ Howard Horn Date: April 13, 2021 | Howard Horn Chief Financial Officer
File and source
- File
- SEC_VIR_8-K_filed2021-04-13_0001193125-21-114677.htm
- Size
- 17,163 bytes
- SHA-256
- a7eebb7c46ab75e21fb4dc0877472aa87866957b9d460bd1cc6ca3f7e3e85a81
- Original
- www.sec.gov